Status: Recruiting
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
Participants needed: 1,000
Trial details
Age: 40-90Biological sex: AllType: ObservationalSponsor: Neurogen Biomarking LLCUpdated: Jul 14, 2026Locations: 5
Eligibility criteria
AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognit...
Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other...